Bendamustine Hydrochloride + Isatuximab
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Amyloidosis
Conditions
Amyloidosis, Light Chain (AL) Amyloidosis
Trial Timeline
Sep 1, 2022 → Jan 1, 2026
NCT ID
NCT04943302About Bendamustine Hydrochloride + Isatuximab
Bendamustine Hydrochloride + Isatuximab is a phase 2 stage product being developed by Sanofi for Amyloidosis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04943302. Target conditions include Amyloidosis, Light Chain (AL) Amyloidosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04943302 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Amyloidosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZN-d5 | Zentalis Pharmaceuticals | Phase 1/2 | 33 |
| VELCADE | Johnson & Johnson | Phase 1/2 | 41 |
| ABBV-383 (Etentamig) | AbbVie | Phase 1/2 | 41 |
| Venetoclax + Dexamethasone + Daratumumab | AbbVie | Phase 1/2 | 41 |
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 33 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | AstraZeneca | Pre-clinical | 23 |
| Carfilzomib + Dexamethasone | Amgen | Phase 1 | 32 |
| Idelalisib | Gilead Sciences | Phase 2 | 51 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Fx-1006A | Pfizer | Phase 2 | 51 |
| tafamidis | Pfizer | Pre-clinical | 22 |
| Cyclophosphamide + Dexamethasone + Elotuzumab + Lenalidomide | Bristol Myers Squibb | Phase 2 | 51 |
| Isatuximab | Bristol Myers Squibb | Phase 2 | 51 |
| Bortezomib + Cyclophosphamide + Dexamethasone + Isatuximab | Sanofi | Phase 1 | 32 |
| NC-503 (Anti-amyloidotic (AA) Agent) | GSK plc | Phase 2/3 | 64 |
| NTLA-2001 + Placebo | Regeneron Pharmaceuticals | Phase 3 | 76 |
| Linvoseltamab | Regeneron Pharmaceuticals | Phase 1/2 | 40 |
| ALN-TTR01 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Patisiran | Alnylam Pharmaceuticals | Phase 3 | 74 |